KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Assets (2016 - 2026)

CareDx's Assets history spans 14 years, with the latest figure at $411.1 million for Q1 2026.

  • On a quarterly basis, Assets fell 16.05% to $411.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $411.1 million, a 16.05% decrease, with the full-year FY2025 number at $413.2 million, down 15.85% from a year prior.
  • Assets hit $411.1 million in Q1 2026 for CareDx, down from $413.2 million in the prior quarter.
  • Over the last five years, Assets for CDNA hit a ceiling of $546.7 million in Q1 2022 and a floor of $411.1 million in Q1 2026.
  • Historically, Assets has averaged $486.1 million across 5 years, with a median of $489.6 million in 2025.
  • Biggest five-year swings in Assets: increased 8.23% in 2025 and later decreased 16.05% in 2026.
  • Tracing CDNA's Assets over 5 years: stood at $543.0 million in 2022, then decreased by 14.03% to $466.8 million in 2023, then grew by 5.19% to $491.0 million in 2024, then dropped by 15.85% to $413.2 million in 2025, then decreased by 0.52% to $411.1 million in 2026.
  • Business Quant data shows Assets for CDNA at $411.1 million in Q1 2026, $413.2 million in Q4 2025, and $432.3 million in Q3 2025.